Results 221 to 230 of about 657,043 (287)

Toxicity Differences Between Microplastics and Nanoplastics in Organs: From Molecular Mechanisms to Potential Therapeutic Strategies

open access: yesMed Research, EarlyView.
This review systematically compares the size‐dependent toxicity of microplastics and nanoplastics in the intestine, liver, kidney, lung, and brain. Particle size determines bioavailability, barrier penetration, and injury mechanisms. Because of their small size and high surface reactivity, NPs readily cross the intestinal epithelium and blood–brain ...
Yixian Cheng   +14 more
wiley   +1 more source

The Microbiome as a Mirror: Distinguishing Healthy Individuals From Chronic Constipated Patients and Identifying Those With Hidden Psychiatric Burden

open access: yesMicrobiota Medicine Research, EarlyView.
Gut microbiota signatures distinguish chronic constipated patients from healthy individuals, supporting noninvasive diagnostic potential. Despite challenges in identifying psychiatric‐related comorbidities, microbial alterations, particularly in neurotransmitter and inflammatory pathways, lay the groundwork for future companion diagnostics and ...
Hongyan Qi   +7 more
wiley   +1 more source

Microbiota Transplantation Effectively Treats Immune Checkpoint Inhibitor‐Associated Colitis: A Multi‐Center, Retrospective Case Series

open access: yesMicrobiota Medicine Research, EarlyView.
ABSTRACT Background Immune‐mediated colitis is an adverse effect of therapy with immune checkpoint inhibitors (ICIs). This study aims to evaluate the efficacy and safety of washed microbiota transplantation (WMT) in patients with ICI‐associated colitis.
Mengyu Huang   +7 more
wiley   +1 more source

Investigation of the Mechanism of Cinnamaldehyde in Irritable Bowel Syndrome Based via Network Pharmacology, Molecular Docking, and Animal Experiments

open access: yesPediatric Discovery, EarlyView.
Through network pharmacology and molecular docking, it has been discovered that CA can target MAOB, among other proteins, to exert a therapeutic effect in IBS. In vivo, CA lowered visceral hypersensitivity, anxiety and depression‐like behaviors, and fecal water content, highlighting its therapeutic potential for IBS via anti‐inflammatory pathways ...
Qingyang Yu   +4 more
wiley   +1 more source

Analysis of C4 Concentrations to Predict Impact of Patient‐Reported Diarrhea Associated With the Ileal Bile Acid Transporter Inhibitor Linerixibat

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 596-605, March 2025.
ABSTRACT Linerixibat, an ileal bile acid transporter (IBAT) inhibitor, is being evaluated for the treatment of pruritus in primary biliary cholangitis (PBC). Diarrhea is commonly reported with this drug class as IBAT inhibition redirects bile acids (BA) to the colon.
Fernando Carreño   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy